In a recent Canadian Medical Association Journal (CMAJ) publication, CITF-funded researchers Drs. Karina Top (Dalhousie University), Manish Sadarangani (University of British Columbia), Jesse Papenburg (McGill University), and led by Drs. Fatima Kakkar and Shaun Morris, described 264 children who were admitted to hospital in Canada with confirmed SARS-CoV-2 infection in 2020.
Canada and other countries globally have authorized different SARS-CoV-2 vaccines, mostly based on findings from clinical trials which have demonstrated a high degree of efficacy against disease.
A recent pre-print (therefore, not yet peer-reviewed) led by CITF-funded researcher Dr. Stephen Hwang from the University of Toronto and Unity Health, explored the prevalence of SARS-CoV-2 among people experiencing homelessness in Toronto during the first wave of the pandemic.
Vaccine safety is evaluated by tracking adverse events following immunization to determine whether such events are linked to the vaccine.
An international team of experts conducted a multi-laboratory evaluation of 21 commercial high-throughput assays used in laboratories to determine whether someone has antibodies to SARS CoV-2 proteins, using 1,000 blood-donor samples.
This commentary From Dr. David Savitz and CITF-funded researcher Dr. Deshayne Fell outlines specific methods that should be implemented in research to more effectively assess the risk of severe COVID-19 among pregnant individuals.
In a recent Short Communication in Preventive Medicine, CITF Leadership Group member Dr. Gina Ogilvie, CITF-funded researcher Dr. Daniel Grace and colleagues explore the mental health of sexual health service clients, an example of a marginalized community. T
A study by researchers at the University of Toronto, in collaboration with CITF-funded researcher Dr. Sasha Bernatsky from the Research Institute of the McGill University Health Centre, observed that people with autoimmune diseases had the same proportion of SARS-CoV-2 positive tests and a similar disease incidence compared to the general population in 2020.
Individuals who have recovered from COVID-19 or who have received SARS-CoV-2 vaccines (mRNA or adenovirus-based) have been shown to have virus-neutralizing activity in their saliva.
In a preprint that has not been peer-reviewed, CITF Leadership Group member Dr. Mel Krajden and colleagues sought to identify factors associated with COVID-19 hospitalization by looking at all individuals with lab-confirmed SARS-CoV-2 in British Columbia as of January 15, 2021.